利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.019 秒)

    Topical Montelukast formulations
    1.
    发明授权
    Topical Montelukast formulations 有权

    公开(公告)号：US11173117B2

    公开(公告)日：2021-11-16

    申请号：US17165574

    申请日：2021-02-02

    申请人： TARO PHARMACEUTICAL INDUSTRIES LTD.

    发明人： Vered Rosenberger ,  Helena Shifrin ,  Irena Oleinik ,  Tzviel Sheskin ,  Ron Schlinger ,  Avi Avramoff

    IPC分类号： A61K9/107 ,  A61K31/47 ,  A61K47/26 ,  A61K47/32 ,  A61K47/10 ,  A61K9/00

    摘要： The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

    TOPICAL MONTELUKAST FORMULATIONS
    4.
    发明申请
    TOPICAL MONTELUKAST FORMULATIONS 有权

    公开(公告)号：US20210393613A1

    公开(公告)日：2021-12-23

    申请号：US17391813

    申请日：2021-08-02

    申请人： TARO PHARMACEUTICAL INDUSTRIES LTD.

    发明人： Vered ROSENBERGER ,  Helena SHIFRIN ,  Irena OLEINIK ,  Tzviel SHESKIN ,  Ron SCHLINGER ,  Avi AVRAMOFF

    IPC分类号： A61K31/47 ,  A61K9/00 ,  A61K9/107 ,  A61K47/10 ,  A61P17/04

    摘要： The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

    TOPICAL MONTELUKAST FORMULATIONS
    5.
    发明申请
    TOPICAL MONTELUKAST FORMULATIONS 有权

    公开(公告)号：US20210236423A1

    公开(公告)日：2021-08-05

    申请号：US17165574

    申请日：2021-02-02

    申请人： TARO PHARMACEUTICAL INDUSTRIES LTD.

    发明人： Vered ROSENBERGER ,  Helena SHIFRIN ,  Irena OLEINIK ,  Tzviel SHESKIN ,  Ron SCHLINGER ,  Avi AVRAMOFF

    IPC分类号： A61K9/107 ,  A61K31/47 ,  A61K9/00 ,  A61K47/32 ,  A61K47/10 ,  A61K47/26

    摘要： The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 μm, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

    Topical carbamazepine formulations
    7.
    发明申请
    Topical carbamazepine formulations 审中-公开
    局部卡马西平配方

    公开(公告)号：US20020198192A1

    公开(公告)日：2002-12-26

    申请号：US10187974

    申请日：2002-07-03

    申请人： Taro Pharmaceutical Industries Ltd.

    发明人： Gad Keren

    IPC分类号： A61K031/55

    CPC分类号： A61K47/24 ,  A61K9/0014 ,  A61K31/00 ,  A61K31/55 ,  A61K45/06 ,  A61K47/06 ,  A61K47/10 ,  A61K47/32 ,  A61K47/44 ,  Y10S514/863 ,  A61K2300/00

    摘要： A therapeutic formulation comprises a topically acceptable semisolid vehicle and carbamazepine, the vehicle consisting of components that are compatible with the carbamazepine, and the carbamazepine being in a concentration sufficient to permit a therapeutically effective amount of the carbamazepine to be absorbed from the formulation into the skin of a patient. The vehicle may be a cream, ointment, or gel. A method of treating a skin condition of a patient such as psoriasis comprises applying carbamazepine topically to the patient's skin until the condition improves. A method of administering carbamazepine to a patient comprises applying a formulation comprising carbamazepine topically to the patient's skin.

    摘要翻译： 治疗性制剂包含局部可接受的半固体赋形剂和卡马西平，所述载体由与卡马西平相容的组分组成，所述卡马西平的浓度足以使治疗有效量的卡马西平从配方吸收到皮肤中 的病人 车辆可以是奶油，软膏或凝胶。 治疗诸如银屑病之类的患者的皮肤状况的方法包括将卡马西平局部施用于患者的皮肤直到病情改善。 向患者施用卡马西平的方法包括将包含卡马西平的制剂局部施用于患者的皮肤。